Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsJohnson & Johnson's fiscal 2025 sales rose about 6% to $94.2 billion, and its net income includes a roughly $7 billion reversal of its talc reserve.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Monday's ETF Movers: IHI, REMX

In trading on Monday, the iShares U.S. Medical Devices ETF is outperforming other ETFs, up about 1.6% on the day. Components of that ETF showing particular strength include shares of Procept…

More from Monday 12 October →